|Structural Type:||[ ]|
Shared Reference Notes
- [1.1] [#Xanthohumol supplementation]
- XN supplementation > decreased plasma insulin concentrations > improved Insulin Resistance. - The intestinal microbiota > metabolizes XN into bioactive compounds, including dihydroxanthohumol > anti-obesity. - XN > increased the relative abundance of three bacteria, Akkermansia muciniphila, Parabacteroides goldsteinii and Alistipes finegoldii.
- some of the positive outcomes of XN are accomplished by increasing #Akkermansia muciniphila, which we also found increased by TXN
- [#Metabolic syndrome] - Xanthohumol (XN) and its derivatives mitigate diet-induced #Obesity-related characteristics of MetS in mice by improving impaired #Glucose and lipid metabolism
- [#Non alcoholic steatohepatitis] - XN and even more so, TXN, attenuates hepatosteatosis by acting as antagonists of PPARγ
- [#Non-alcoholic fatty liver disease] - XN also exhibits hepatoprotective effects in animal models of MAFLD and other liver-damaging conditions
- - TXN treatment also reduced levels of inflammation-inducing microbes, such as #Oscillibacter valericigenes, that lead to adverse metabolic phenotypes.
- - TXN attenuates macrophage inflammatory processes in adipose tissue.